



FY 2025 – Preliminary Unaudited Revenue

*SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION,
AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES*



03 February 2026

Disclaimer

This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at <https://www.medacta.com/EN/investors>.

FORWARD-LOOKING INFORMATION

This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions. There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group

operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved.

ALTERNATIVE PERFORMANCE MEASURES

This Presentation may contain information regarding alternative performance measures. Definitions of these measures may be found on the financial reports available on our website at <https://www.medacta.com/EN/investors>.

THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP

Related Trademarks

Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, MyKA™, NextAR™, NextAR™ Spine.

Not all products are available in all countries. Product availability is dependent upon the registration requirements for your country. All trademarks and registered trademarks are the property of their respective owners.



FRANCESCO SICCARDI

Chief Executive Officer



Continued significant above-market growth

FY 2025 revenue in EUR*

683.8 m

FY 2025 revenue growth*

18.5 % in cc**

15.8 % in EUR

Differentiating innovations

*with aim to improve patient outcomes
& healthcare sustainability*


Education and personalized training of surgeons

*thereby acquiring new surgeons
across all business lines*

Team expansion 258 new employees

*to increase network of surgeons
& foster further growth*

Continued high teens revenue growth



- FY 2025 revenue growth* of 18.5% yoy
- Outgrowing market** by 4.3x
- Revenue CAGR* (FY 2021 - FY 2025) of 17.4%

Medacta's success pillars for above-market growth

1

Differentiating innovations

*with aim to improve patient outcomes
& healthcare sustainability*

2


Education and personalized training of surgeons

*thereby acquiring new surgeons
across all business lines*


3

Team expansion


*to increase network of surgeons
& foster further growth*



Substantial growth across all geographies




FY 2025 geographic revenue distribution




- NORAM and APAC surging respectively, 19.0% and 23.0% yoy
- EMEA: outstanding above-market growth in mid-teens
- LATAM: growing more than 40% yoy

Excellent above-market growth across all business lines




FY 2025 revenue distribution by business line



Notes
* In constant currency
** Extremities includes Shoulder and Sportsmed

Continued double-digit growth in Hip




Hip – FY 2025

- Growth mainly attributable to Medacta's Anterior Minimally Invasive Surgery (AMIS) platform
- Outstanding growth in APAC and NORAM
- Almost 3 x above-market growth 2025E** yoy

AMIS[®] Experience
ANTERIOR MINIMALLY INVASIVE SURGERY
IN HIP REPLACEMENT

Excellent expansion in Knee




Knee – FY 2025

- Outstanding performance due to GMK SpheriKA and MyKA, Medacta's personalized Kinematic Alignment platform
- NORAM and EMEA grew in low twenties, closely followed by APAC
- 4.6x above-market growth 2025E** yoy



Outstanding growth in Spine




Spine – FY 2025

- Solid revenue growth strongly supported by Medacta's technologies, particularly by NextAR Spine and the NextAR Rod Optimizer
- Particularly strong performance in EMEA, followed by APAC
- 3.5x above-market growth 2025E** yoy

Selection of pre-contoured rods



Continued superior growth in Extremities



Extremities – FY 2025

- Expansion primarily due to Medacta Shoulder System, supported by advanced technologies such as MyShoulder and NextAR
- Sportsmed portfolio strengthened with acquisition of Parcus
- 3.5x above-market growth 2025E** yoy in Shoulder and more than 3x in Sportsmed (organic)

Outlook

Outlook 2025

Medacta is targeting a revenue growth in the range of 16% to 18% in constant currency and an adjusted EBITDA margin of around 28% before any currency effects, including the recent Parcus acquisition, subject to unforeseen events.

Mid-term outlook

Revenue compound annual growth rate (CAGR) (2024-2027E) in constant currency is expected to be in the range of 10% to 14%, and an adjusted EBITDA margin targeted to be around 28% before any currency effects.

Tariffs

Medacta remains not impacted by the US tariffs and will continue to monitor the development.

Key Messages

- **Excellent continued above-market FY 2025 revenue growth of 18.5% yoy in constant currency as result of**
 - *Differentiating innovations to improve patient outcomes and healthcare sustainability*
 - *Education and personalized training of surgeons*
 - *Further expansion of sales reps and team*
- **Our aim: Continuing to outgrow the market**

Thank you

to all our employees, clients, suppliers and partners worldwide



MEDACTA.COM
